Loss of mTOR leads to significant reduction of monocytes in ER-mTOR mice. The cells of spleens, peritoneal cavity, and blood from tamoxifen-treated WT and ER-mTOR KO mice were stained with anti-CD11b mAb and anti-Ly6C mAb or anti-CCR2 mAbs. (A) Representative fluorescence-activated cell sorter analysis of spleens, peritoneal cavity, and blood monocytes for staining CD11b⁺Ly6C^hi was shown. The percentages (B) and cell numbers (C) of CD11b⁺Ly6C^hi cells in peritoneal cavity, spleens, and blood from tamoxifen-treated WT and ER-mTOR KO mice were compared. (D) Representative fluorescence-activated cell sorter analysis of spleens, peritoneal cavity, and blood monocytes for staining CD11b⁺CCR2⁺ was shown. The percentages (E) and cell numbers (F) of CD11b⁺CCR2⁺ cells in peritoneal cavity, spleen, and blood from tamoxifen-treated WT and ER-mTOR KO mice were shown. Data are representative of 5 independent experiments. *P < .05; **P < .01; ***P < .001 compared between WT and ER-mTOR KO mice.